首页 > MatTek > MatTek/Psoriasis/psoriasis/1 Ea

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

MatTek/Psoriasis/psoriasis/1 Ea

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

psoriasis

品牌：

MatTek

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Psoriasisisachronicinflammatoryskindiseasecharacterizedbyepidermalhyperplasia(Acanthosis)withelongatedridgesandabnormaldifferentiationofepidermalkeratinocytes,dermalangiogenesis,abnormalaccumulationofpolymorphonuclearleukocytes,infiltrationofactivatedTcellsanddendriticcells,andincreasedcytokinelevels.MatTekhasdevelopedinvitromodelofPsoriasistoenablethestudyofthedisease,andtoscreentherapeuticcandidatesforsafetyandefficacy.Technology:MatTek’sdiseased3Dmodelofpsoriasisisproducedfromnormalhumanepidermalkeratinocytesandpsoriaticfibroblastsharvestedfrompsoriaticlesions.Thecellsareculturedonspeciallypreparedcellcultureinsertsusingserumfreemediumtoformamultilayered,highlydifferentiatedtissue.ThePsoriasistissuesmaintainapsoriaticphenotypeasevidencedbyincreasedbasalcellproliferation,expressionofpsoriasis-specificMarkersandelevatedreleaseofpsoriasis-specificcytokines.Morphologically,thetissuemodelcloselyparallelslesionalpsoriatichumantissues.Thismodelprovidesresearcherswithahumanrelevant,highlycontrolledinvitromodeltoassessthesafetyandefficacyofleadtherapeuticcompoundsandtostudyotherbasicpsoriasisBIOLOGyphenomena.Thepsoriasistissuemodelexhibitsapsoriaticphenotypeasevidencedbyincreasedexpressionofpsoriasis-associatedmarkersincludinghumanβ-defensin-2(HBD2),psoriasin,SKALP/elafin,keratinocytehyperproliferativecellsandproinflammatorycytokines/chemokinessuchasIL-6,IL-8,GM-CSF,andIP-10. Additionally,MatTek’sPsoriasismodelcanbeproducedfrom6differentdonorsallowingforthestudyoftherapeuticswhileaccountingforbiologicalvariABIlitybetweendonors.TheinvitroPsoriasismodelisresponsivetomarketedanti-psoriatictherapeuticsandisamenabletomodelskin–immunesysteminteractionswiththeexogenousadditionofsolubleimmunecellfactors. Applications:Anti-PsoriasisDrugScreeningThemodelprovidesresearcherswithauseful,invitromeanstoassessthepre-clinicalsafetyandefficacyofleadtherapeuticcompounds.PsoriasisApplicationNotePsoriasisDiseaseResearchThetissuemodelcloselyparallelslesionalpsoriatichumantissuesintermsofmorphologyandcytokineexpression.Thismodelprovidesresearcherswithauseful,invitromeanstostudypsoriasisbiologyphenomena.Searchourlibraryoftechnicalpapersformoreinformation.a[rel~="mtli_filesize81384kB"]:after {content:" (813.84 kB)"}TechSpecs:Tissue:Kit:ThePsoriasisTissueKit(SOR-300-FT)consistsof24tissues.Substrate:MilliporeMillicell™Cellcultureinsertused.Poresize=0.4μm,Diameter=0.8cm,Surfacearea=0.6cm2.Culture:Atairliquidinterface(apicaltissuesurfaceexposedtotheatmosphere).Histology:8-12celllayersplusstratumcorneum(basal,spinous,andgranularlayers).LotNumbers:Tissuelotsareproducedeveryotherweekandareassignedaspecificlotnumber.Aletterofthealphabetisappendedtotheendofthelotnumbertodifferentiatebetweenindividualkitswithinagivenlotoftissues.Alltissuekitswithinalotareidenticalinregardstocells,medium,handling,cultureconditions,etc.Shipment:At2-8°Conmedium-supplemented,agarosegelsin24-wellplates.Shipmentday:EveryotherMonday.Delivery:TuesdaymorningviaFedExpriorityservice(US).OutsideUS:Tuesday-Thursdaydependingonlocation.Shelflife:Includingtimeintransit,tissuesmaybestoredintheiroriginalpackageat2-8°Cforupto4dayspriortouse.Thebestreproducibilitywillbeobtainediftissuesareusedconsistentlyonthesameday,e.g.Tuesdayafternoonorfollowingovernightstorageat2-8°C(Wednesdaymorning).Extendedstorageperiodsarenotrecommended.Lengthofexperiments:Culturescanbecontinuedforupto2weekswithgoodretentionofnormalepidermalmorphology.Culturesmustbefedeveryotherdaywith5.0mlofSOR-300-FT-MMmedium.Culturestands(MatTekpart#:MEL-STND)arerequiredforexperimentsinexcessof24hrs.Alternativetissues:SOR-300-FT-ABF:Antibiotic-freetissue.Forlast3daysofculture,gentamicinisomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.SOR-300-FT-AFF:Anti-fungal-freetissue.Forlast3daysofculture,Amphotericinisomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.SOR-300-FT-AFAB:Antibiotic,anti-fungal-freetissue.Forlast3daysofculture,gentamicinandAmphotericinareomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.SOR-300-FT-CTR:NormalhealthycontroltissueforpsoriasisexperimentsCells:Type:Normalhumanepidermalkeratinocytes(NHEK);psoriatichumandermalfibroblasts(PHDF).Derivedfrom:Neonatal-foreskintissue(NHEK);adultpsoriaticexplants(PHDF)Screenedfor:HIV,Hepatitis-B,Hepatitis-C,andmycoplasma.Medium:Basemedium:Dulbecco’sModifiedEagle’sMedium(DMEM).Growthfactors/hormones:Epidermalgrowthfactor,insulin,hydrocortisoneandotherproprietarystimulatorsofepidermaldifferentiation.Serum:None.Antibiotics:Gentamicin5µg/ml(10%ofthenormalgentamicinlevel).Anti-fungalagent:AmphotericinB0.25µg/ml.pHIndicator:Phenolred.Otheradditives:Lipidprecursorsusedtoenhanceepidermalbarrierformation(proprietary).Alternatives:Phenolred-free(SOR-300-FT-PRF),antibiotic-free(SOR-300-FT-ABF),anti-fungal-free(SOR-300-FT-AFF),orhydrocortisone-freemediumandtissue(SOR-300-FT-HCF)areavailable.Agentsareremoved3dayspriortoshipment.Assay/Maintenancemedium:SOR-300-FT-MMisusedforequilibrationoftissuesfollowingshipmentandformaintenanceoftheSOR-300-FTtissuesincultureduringexperiments.QualityControlandSterility:Visualinspection:Alltissuesarevisuallyinspectedandifphysicalimperfectionsarenoted,tissuesarerejectedforshipment.End-usetesting:Tissuesareexposedto1%TritonX-100for4,6,8and10hours.Thetimeofexposurerequiredtoreducethetissueviability(ET-50)usingtheMTTviabilityassayisdetermined(SeeMatTekPsoriasisTissueuseprotocol)foreachlotoftissue.ET-50’sgenerallyfallwithintherangeof6.0-12.0hours.ET-50’sincustomers’labmaydifferslightlyfromtheMatTekresults.Inaddition,qPCRdataforpsoriasisrelatedgeneswillbemonitored.Increasesof>5foldforpsoriasin,humanbeta-defensin-2andelafinareexpected.Sterility:Allmediausedthroughouttheproductionprocessischeckedforsterility.Maintenancemediumisincubatedwithandwithoutantibioticsfor1weekandcheckedforsterility.Theagarosegelfromthe24-wellplateusedforshippingisalsoincubatedfor1weekandcheckedforanysignofcontamination.Screeningforpathogens:AllcellsarescreenedandarenegativeforHIV,hepatitisBandhepatitisCusingPCR.However,noknowntestmethodcanoffercompleteassurancethatthecellsarepathogenfree.Thus,theseproductsandallhumanderivedproductsshouldbehandledatBSL-2levels(biosafetylevel2)orhigherasrecommendedintheCDC-NIHmanual,“Biosafetyinmicrobiologicalandbiomedicallaboratories,”1998.Forfurtherassistance,pleasecontactyoursiteSafetyOfficerorMatTektechnicalservice.Notificationoflotfailure:IfatissuelotfailsourQCorsterilitytesting,thecustomerwillbenotifiedandthetissueswillbereplacedwithoutchargewhenappropriate.BecauseourQCandsterilitytestingisdonepost-shipment,notificationwillbemadeassoonaspossIBLe(Undernormalcircumstances,ET-50failureswillbenotifiedbyThursday5pm;sterilityfailureswillbenotifiedwithin8daysofshipment).

MatTek公司是麻省理工学院两个化学工程教授于1985成立的科技公司。1991年，该公司利用其核心的聚合物表面改性技术进入新兴的组织工程领域，目前已成长为的组织工程技术公司，致力于生产创新性的3D重构人体组织模型，该模型相较于传统2D细胞模型具有更可靠的实验结果。其生产的重构皮肤，眼部和呼吸道组织模型已广泛应用于化妆品，化工，医药和家用产品等行业的毒理学监控（OECD，欧盟的指导方针）及毒理学研究。

MatTek公司的基于人体细胞的3D皮肤模型EpiDerm于1993年研发上市，立即获得巨大的成功。从此MatTek通过以下方式彻底改变了基于人体细胞的体外模型市场：（1）低成本（降低50-80％的成本）；（2）通过发表质量控制标准（同时具备阳性和阴性对照）以确保可为行业及监管机构接受的高可重复性水平；（3）优化研究人员的实验结果。通过创造性使用非动物的体外测试，融合降低(直接/间接)成本的强大协同效应及显著提高的产品质量，MatTek极大的降低产品成本、提高实验室效率及高质量的高可重复性产品，减少实验动物的使用，具有无可超越的长期组织可重复性；3-D仿真结构；高度分化的组织模型；代谢和分裂活性；源于正常的人体细胞；培养、操作简便；无血清培养；可定量的客观检测；物美价廉的优点。因而使得MatTek人细胞来源的体外组织模型被包括美国、加拿大、欧洲、日本和东亚的众多跨国公司与研究机构采用。

目前MatTek公司的产品主要包括EpiDerm（皮肤模型）、MelanoDerm（黑色素模型）、EpiOcular（眼周表皮模型）、EpiAirway呼吸道上皮模型）、EpiDermFT (全厚的皮肤模型) 、EpiVaginal（阴道上皮模型）、EpiOral（口腔上皮模型）、 EpiGingivalTM（牙龈上皮模型）、Psoriasis tissue（牛皮癣组织模型）及树突细胞。